SMS Lifesciences India Limited (SMSLIFE.NS)
- Previous Close
1,308.30 - Open
1,290.50 - Bid --
- Ask --
- Day's Range
1,280.10 - 1,315.00 - 52 Week Range
648.40 - 1,749.65 - Volume
893 - Avg. Volume
2,760 - Market Cap (intraday)
3.915B - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
16.98 - EPS (TTM)
76.27 - Earnings Date May 26, 2025 - May 30, 2025
- Forward Dividend & Yield 1.50 (0.11%)
- Ex-Dividend Date Sep 23, 2024
- 1y Target Est
--
SMS Lifesciences India Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers APIs in various therapeutic areas, such as anti ulcer, erectile dysfunction, anti gout, anesthesia, anti infective, anti obesity, antifungal, anti convulsant, anti emetic, ophthalmic, anti worm, and antiemetic. It is also developing APIs in the areas of anti depressant, anti psychotic, anti hypertension, veterinary, antiviral, and anticoagulant. In addition, the company offers intermediates in the anti ulcer, anti migraine, anti hypertension, erectile dysfunction, anti cancer, antifungal, anti obesity, anti emetic, anti depressant, anti worm, anti gout, anti infective, anti convulsant, antiviral, and anesthesia. It also exports its products. SMS Lifesciences India Limited was founded in 1990 and is based in Hyderabad, India.
www.smslife.inRecent News: SMSLIFE.NS
View MorePerformance Overview: SMSLIFE.NS
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SMSLIFE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SMSLIFE.NS
View MoreValuation Measures
Market Cap
3.93B
Enterprise Value
4.84B
Trailing P/E
17.17
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.17
Price/Book (mrq)
2.11
Enterprise Value/Revenue
1.43
Enterprise Value/EBITDA
9.03
Financial Highlights
Profitability and Income Statement
Profit Margin
6.67%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
3.46B
Net Income Avi to Common (ttm)
230.4M
Diluted EPS (ttm)
76.27
Balance Sheet and Cash Flow
Total Cash (mrq)
11.92M
Total Debt/Equity (mrq)
45.35%
Levered Free Cash Flow (ttm)
--